
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Pulmatrix Inc (PULM)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PULM (1-star) is a SELL. SELL since 4 days. Profits (-22.44%). Updated daily EoD!
1 Year Target Price $10
1 Year Target Price $10
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.7% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.57M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.45 | 52 Weeks Range 1.78 - 10.40 | Updated Date 06/30/2025 |
52 Weeks Range 1.78 - 10.40 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -506.98% |
Management Effectiveness
Return on Assets (TTM) -31.67% | Return on Equity (TTM) -93.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16044995 | Price to Sales(TTM) 13.31 |
Enterprise Value 16044995 | Price to Sales(TTM) 13.31 | ||
Enterprise Value to Revenue 8.35 | Enterprise Value to EBITDA 1.57 | Shares Outstanding 3652280 | Shares Floating 3628107 |
Shares Outstanding 3652280 | Shares Floating 3628107 | ||
Percent Insiders 0.66 | Percent Institutions 8.81 |
Analyst Ratings
Rating 1 | Target Price 10 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pulmatrix Inc
Company Overview
History and Background
Pulmatrix Inc. was founded in 2003. It is a biopharmaceutical company focused on developing inhaled therapies to prevent and treat respiratory diseases. It has transitioned from a broader respiratory focus to concentrating on severe asthma and fungal infections.
Core Business Areas
- iSPERSE Technology: Pulmatrix's proprietary iSPERSE technology enables the delivery of small and large molecules directly to the lungs via dry powder formulations, enhancing efficacy and reducing systemic side effects.
- Pulmazole: An inhaled formulation of itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. Currently in clinical development.
- PUR1900: A pipeline product currently in preclinical development. It is a narrow spectrum kinase inhibitor targeting neutrophilic asthma.
Leadership and Structure
The leadership team includes highly experienced professionals in drug development, finance, and management. The organizational structure includes research & development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Pulmazole: Pulmazole is Pulmatrix's lead product candidate for treating ABPA. Currently in Phase 3 clinical trials. Market share data is not available yet. Potential competitors include oral itraconazole formulations and other antifungal treatments, such as those by Viatris (MYL) and Teva (TEVA).
- iSPERSE Technology: Pulmatrix licenses its iSPERSE technology to other pharmaceutical companies for use in their inhaled drug products. No direct revenue available. Competitors include other drug delivery technologies and companies like MannKind (MNKD) which specialize in inhaled product technologies.
Market Dynamics
Industry Overview
The respiratory drug market is substantial and growing, driven by increasing prevalence of asthma, COPD, and fungal infections. There is a high demand for targeted drug delivery systems to improve efficacy and reduce systemic side effects. The market is competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
Pulmatrix is positioned as a specialty pharmaceutical company with a focus on inhaled therapies. Its proprietary iSPERSE technology provides a competitive advantage by enabling efficient delivery of drugs directly to the lungs. Their Pulmazole targets a specific niche within the larger asthma and antifungal market.
Total Addressable Market (TAM)
The TAM for ABPA treatment is estimated to be in the hundreds of millions of dollars globally. Pulmatrix is positioned to capture a portion of this market with Pulmazole, if approved. The TAM for iSPERSE is harder to quanify as it is tied to the value of the new drugs it enables.
Upturn SWOT Analysis
Strengths
- Proprietary iSPERSE technology
- Targeted drug delivery
- Lead product in Phase 3 clinical trials
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Single lead product candidate
- Relatively small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of iSPERSE technology applications
- Regulatory approval and commercialization of Pulmazole
- Development of new inhaled therapies
Threats
- Clinical trial failures
- Competition from existing treatments
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MYL
- TEVA
- MNKD
- GILD
Competitive Landscape
Pulmatrix's iSPERSE technology and focus on inhaled therapies differentiate it from larger pharmaceutical companies. However, it faces competition from companies with established products and greater financial resources. Its ability to secure partnerships will be crucial for long-term success.
Growth Trajectory and Initiatives
Historical Growth: Pulmatrix's growth has been driven by advancements in its clinical programs and strategic partnerships. The past few years have seen a shift to focus on Pulmazole. There has been moderate growth in R&D investments.
Future Projections: Future growth is dependent on the success of Pulmazole's clinical trials and eventual commercialization. Analyst estimates vary, but project substantial revenue growth if Pulmazole is approved.
Recent Initiatives: Focus on advancing Pulmazole through Phase 3 clinical trials. Seeking strategic partnerships to support commercialization. Continued investment in research and development of iSPERSE technology.
Summary
Pulmatrix is a biopharmaceutical company with promising iSPERSE technology and a lead product, Pulmazole, in late-stage development. The company's future hinges on the success of Pulmazole, and it faces challenges related to funding and competition. Strategic partnerships and further development of its technology are essential for growth. Financial resources are tight and should be managed well.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pulmatrix Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Industry Publications
- Corporate press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data may be estimated and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulmatrix Inc
Exchange NASDAQ | Headquaters Framingham, MA, United States | ||
IPO Launch date 2014-03-21 | Interim CEO & Interim CFO Mr. Peter Ludlum CMA, MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.pulmatrix.com |
Full time employees 2 | Website https://www.pulmatrix.com |
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.